Araştırma Makalesi
BibTex RIS Kaynak Göster

Booster Dose Vaccine Response among Children Who were Primary Hepatitis B Vaccine Non-Responders and Sensitive Groups Concerning Vaccine Response

Yıl 2019, , 160 - 164, 24.05.2019
https://doi.org/10.12956/tjpd.2018.351

Öz

Objective: In this study, booster dose vaccine response was evaluated after performing a vaccine schedule at 0,

1st and 6th months among 83 children aged between 2 and 16 years who were primary hepatitis B vaccine nonresponders

and we tried to determine which groups were sensitive concerning vaccine response.

Material and Methods: Euvax B vaccine which included 10 μg HBsAg was administered in 3 doses for the second

time at 0, 1 and 6 months as 0.5 ml intramuscularly in the deltoid muscle to 83 healthy children aged between 2 and 16

years who were primary hepatitis B vaccine non-responders and their vaccine status was determined with tests before

minor surgery. Blood tests were taken three times from children at 1, 6 and 7 months after the first vaccination and anti-

HBs titer was evaluated by using enzyme-linked immunosorbent assay technique.

Results: The mean age of the children was 9.3±3.6 years (2-15,9 years). The anti-HBs geometric mean concentration

was found to be 537.97±377.51 mIU/mL (0.6-1000) after the first vaccination, as 309.33± 337.45 mIU/mL (8-1000)

after the second vaccination and as 609.78±347.43 mIU/mL (11.1-1000) following the third vaccination. Anti-HBs

positive conversion rates in T1 were compared in 81 children who had been checked after the first vaccination and anti-

HBs positive conversion rates were found to be significantly lower in children whose anti-HBs titer was under 1 mlU/ml

before vaccination (p=0,01, Z -3.29, U 469). There was no difference concerning T6 and T7 between these two groups.

Anti-HBs positive conversion rates in T6 and T7 were found to be significantly higher in children with malnutrition

(p=0.008, Z -2.56, U 60.5, p=0.03, Z -2.11, U 26.5).

Conclusion: When observing the rapid decrease in T6 in contrast with the two dose vaccination, it is thought that anti-

HBs seroconversion rates and anti-HBs geometric mean concentration are related with reminding, anti-HBs titer before

vaccination and checking time of anti-HBs rather than the number of reminding doses. In fact, we believe that 3 dose






vaccination is better among those children whose anti-HBs titer is under <1 mIU/mL and who have malnutrition.

Kaynakça

  • 1. Immunization Coverage. Availablefrom:http://www.who.int/mediacentre/ factsheets/fs378/en/. Accessed date: 1 Haziran, 2016
  • 2. Zhuang GH,Yan H, Wang XL. Risk factors of and mechanism for non-responsiveness to hepatitis B vaccination. Zhonghua Gan Zang Bing Za Zhi 2006;14:157-60.
  • 3. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1–8.
  • 4. http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html (8.5.2017)
  • 5. Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: A systematic review. BMC Infectious Diseases 2011;11:337.
  • 6. Bonanni P, Pesavento G, Boccalini S, Bechini A. Perspectives of public health: Present and foreseen impact of vaccination on the epidemiology of hepatitis B. J Hepatol 2003;39:224-9.
  • 7. Ozmert EN. Dünya’da ve Türkiye’de aşılama takvimindeki gelişmeler. Çocuk Sağlığı ve Hastalıkları Dergisi 2008;51:168-75.
  • 8. Jafarzadeh A, Zarei S, Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine 2008;26:269-76.

Birincil Hepatit B Aşı Yanıtsız Çocuklarda Hatırlatma Doz Aşı Yanıtları ve Aşı Yanıtında Hassas Gruplar

Yıl 2019, , 160 - 164, 24.05.2019
https://doi.org/10.12956/tjpd.2018.351

Öz

Amaç: Çalışmada birincil hepatit B aşı yanıtsız 2-16 yaş aralığındaki 83 çocukta, 0, 1 ve 6. ay aşı şeması uygulanarak


elde edilen hatırlatma doz aşı yanıtları değerlendirilmiş ve aşı yanıtında hassas gruplar belirlenmeye çalışılmıştır.


Gereç ve Yöntemler: Küçük cerrahi girişimler öncesi yapılan tetkikler sonrasında birincil hepatit B aşı yanıtsızlığı saptanan


2-16 yaş aralığındaki sağlıklı 83 çocuğa, 2. kez 0, 1 ve 6. aylarda 3 doz 10 μg HBsAg içeren Euvax B aşısı deltoid


kasa 0.5ml kas içine uygulanmıştır. Çocuklardan birinci aşıdan 1, 6 ve 7. ay sonra olmak üzere, 3 kez kan alınarak anti-


HBs titresi enzyme-linked immunosorbent assay tekniği ile değerlendirilmiştir.


Bulgular: Çocukların yaş ortalaması 9.3±3.6 yıl (2-15.9) bulunmuştur. Birinci aşı sonrası anti-HBs ortalama geometrik


konsantrasyonu 537.97±377.51 mIU/mL (0.6-1000), 2. aşı sonrası 309.33± 337.45 mIU/mL (8-1000), 3. aşı sonrası


609.78±347.43 mIU/mL (11.1-1000) bulunmuştur. Birinci aşı sonrası tetkik yapılabilen 81 çocuk arasında T1’de anti-


HBs-positive serokonversiyon oranı, aşı öncesi anti-HBs titresi 1 mIU/mL’nin altında olan çocuklarda diğer gruba göre

istatistiksel anlamlı biçimde daha düşük bulunmuştur (p=0.01, Z -3.29, U 469). Bu 2 grup arasında T6 ve T7’de istatistiksel fark saptanmamıştır.

Malnütrisyonlu hastalarda T6 ve T7’de anti-HBs positive serokonversiyon oranı diğer gruba göre istatistiksel anlamlı olarak daha

yüksek bulunmuştur (p=0.008, Z -2.56, U 60.5, p=0.03, Z -2.11, U 26.5).

Sonuç: İki doz aşıya rağmen T6’daki hızlı düşüşe bakıldığında, anti-HBs serokonversiyon oranı ve anti-HBs ortalama geometrik konsantrasyon

değerleri hatırlatma doz sayısından ziyade, hatırlatma yapılmasına, aşı öncesi anti-HBs titresine ve anti-HBs titresi bakma zamanıyla

ilgili gözükmektedir. Ancak, aşı öncesi anti-HBs titresi <1 mIU/mL olanlar ve malnütrisyonlu çocuklarda 3 doz aşılamanın daha doğru






olacağı kanaatindeyiz.

Kaynakça

  • 1. Immunization Coverage. Availablefrom:http://www.who.int/mediacentre/ factsheets/fs378/en/. Accessed date: 1 Haziran, 2016
  • 2. Zhuang GH,Yan H, Wang XL. Risk factors of and mechanism for non-responsiveness to hepatitis B vaccination. Zhonghua Gan Zang Bing Za Zhi 2006;14:157-60.
  • 3. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1–8.
  • 4. http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html (8.5.2017)
  • 5. Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: A systematic review. BMC Infectious Diseases 2011;11:337.
  • 6. Bonanni P, Pesavento G, Boccalini S, Bechini A. Perspectives of public health: Present and foreseen impact of vaccination on the epidemiology of hepatitis B. J Hepatol 2003;39:224-9.
  • 7. Ozmert EN. Dünya’da ve Türkiye’de aşılama takvimindeki gelişmeler. Çocuk Sağlığı ve Hastalıkları Dergisi 2008;51:168-75.
  • 8. Jafarzadeh A, Zarei S, Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine 2008;26:269-76.
Toplam 8 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular İç Hastalıkları
Bölüm ORIGINAL ARTICLES
Yazarlar

Aysun Kara Uzun

Yayımlanma Tarihi 24 Mayıs 2019
Gönderilme Tarihi 16 Şubat 2019
Yayımlandığı Sayı Yıl 2019

Kaynak Göster

Vancouver Kara Uzun A. Booster Dose Vaccine Response among Children Who were Primary Hepatitis B Vaccine Non-Responders and Sensitive Groups Concerning Vaccine Response. Türkiye Çocuk Hast Derg. 2019;13(3):160-4.

13548  21005     13550